Pricing critical illness (CI) insurance necessitates a view of the future, informed by trends in past disease incidence rates. One of the main CI conditions is cancer. Examples from Asia show that population incidence rates for some of the most prevalent cancers have notably improved in recent years.
Not incorporating this short- to medium-term experience in CI trend assumptions could lead to a sizeable over-estimation of future claim costs, and therefore to overpricing.
As shown in Figure One and Figure Two (see below) incidence rates for many of the most prevalent male cancers have improved, or continued to improve, after 2011 (most notably for colon and stomach cancer). A shift in incidence rates was also observed in Japan in 2011.
Colon cancer incidence deteriorated at a rate of 5.9% for more than 10 years and then improved at a trend of minus 5% since 2011. Incidence trends based on data from 1999-2011 would therefore be more pessimistic than those calculated on data from 2011-2016. For a male non-smoker aged 45, incidence trends based on 1999-2011 data would potentially overestimate the present value of future claims by 37% for stomach cancer and 120% for colon cancer.
This has a significant impact on CI pricing. For example, for South Korea, for all male cancers – an assumed arbitrary worsening trend of 1.5% instead of an improving trend of minus 2.6% for 10 years, which potentially overstates the current value of claims by 18%. A book of business/treaty last priced in 2011 could have been overpriced by 18%.
Figure One: Age-standardised population incidence rates for the most prevalent male cancers 1999-2016, South Korea. Trends notably improved after 2011. Data source: Korea Central Cancer Registry (KCCR) [1].
Will the trend continue?
Despite the observed improvements in stomach and colon cancer in South Korea, 2016 (the most recent year) data indicates a flattening. Although only one year, several risk factors indicate that improvement will continue in the short to medium term (next five to 10 years), but is likely to flatten in the long term. Factors include:
- The prevalence of Helicobacter pylori in Korean adults has fallen constantly by 1.5% per year since 1998. At the same rate, it would take another 20 years to reach western levels.
- Smoking rates are likely to continue to decline, suggesting a continued improvement given the lag between cause and effect, at least in the short term.
- If eligibility for screening and removal of pre-cancerous colon polyps widens, as is likely, and given lags of up to 10 years for polyps to become cancerous, improvements can be expected for years to come.
- The increasing discovery of early-stage male stomach cancers is an indication of earlier screening. However, given that over 70% of those eligible are already being screened, this risk factor is likely to cause a flattening in future incidence rates.
Figure Two: Empirically calculated incidence trends for the most prevalent male cancers, South Korea, using 1999-2011 and 2011-2016 population data. The two periods lead to distinctly different trend rates on which to price future CI business, adding complexity to deriving long-term incidence trends. Data source: KCCR.
Updating trend assumptions
The observations highlight the importance of regularly monitoring cancer incidence trends, understanding the evolving risk factors and updating trend assumptions. Of course, across all cancers, improving trends in some may offset worsening trends in others; in Singapore, for example, worsening incidence trends in females for breast cancer are offsetting improving incidence trends in colon and lung cancer.
It is recommended therefore that short- to medium-term trending for countries where data is available should be guided (but not dictated) by relevant, recent historic experience. This can then be blended into a long-term trend assumption that the pricing actuary considers reasonable given not just incidence data but all relevant risk factors including medical developments, lifestyle changes and screening programs.
This article is written by CJ Sadler who is a senior pricing actuary life and health at PartnerRe; he is based in Hong Kong.
Reference
-
IFRS 17: Making your financial controls automation truly work for you
- September 26
Shifting towards a more automated and streamlined workstream can free up time for insurers to critically analyse results that inform future financial planning.
-
Flood resilience: Water, water everywhere…
- September 11
Floods are one of the most complex natural perils with highly localised impacts, making them challenging to insure and data is key to the effective design of an affordable product to protect the vulnerable.
-
Maritime energy transition: Data dialogue key to achieving decarbonisation goals
- August 3
Collaboration and shared learning amongst stakeholders will be vital to getting full value from the data captured as well as in achieving regulatory goals. The International Maritime Organisation’s (IMO) greenhouse gas (GHG) strategy is to reach net-zero emissions from international shipping by or around 2050, and there are various checkpoints to meet along the way. […]
-
Contentious losses: Evidence-led forensic investigations stand the test of time
- May 17
Even minor cracks in evidence capture will become exposed when it comes to recovery and repudiation. Forensic investigations form part and parcel of many insurance claims in the Asia-Pac region. Whether a loss is complex, costly, or if there are expected to be questions down the line around causation and liability, insurers and their loss […]
-
AXA XL | Low and no-cost cybersecurity actions for companies
Considering the increasing frequency of attacks, the evolving threat landscape, including the use of AI to launch more sophisticated attacks, companies today can’t afford to ignore the possibility of being targeted by cybercriminals.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
CJ Sadler, PartnerRe
The impact of improving cancer rates on critical illness pricing
CJ Sadler, PartnerRe